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Introduction
Activated synovial fibroblasts (SFB) appear to play a major
role in the pathogenesis of rheumatoid arthritis (RA) [1,2].
It has been speculated that their ability to induce and
perpetuate inflammation, as demonstrated in transfer
experiments in mice with SCID (severe combined
Abstract
Constitutive mRNA expression and secretion of proinflammatory and anti-inflammatory cytokines was
comparatively analyzed in rheumatoid arthritis (RA) synovial fibroblasts (SFB), isolated from primary
culture or derived by repeated passage; normal-skin fibroblasts were used as controls. First-passage
RA-SFB (n=3) secreted large amounts of IL-6 (15,800 ± 2,110 pg/ml; mean ± SEM), but only limited
amounts of tumor necrosis factor (TNF)-α (22.1 ± 1.1 pg/ml) or IL-10 (35.7 ± 34.2 pg/ml; only one of
three samples was positive). IL-1β, IL-15, and IL-18 were not detectable at the protein level and showed
very low mRNA levels by semiquantitative RT-PCR. In repeated-passage RA-SFB (tenth passage),
protein secretion was significantly lower for IL-6 (one-twentieth of the initial level) and TNF-α (two-
thirds), and markedly reduced for IL-10 (one-quarter, with only one of three samples positive). While the
decrease of IL-10 protein from first to tenth passage was paralleled by a corresponding decrease of
mRNA, the relative mRNA levels for IL-6 and TNF-α were actually increased (20-fold and 300-fold,
respectively), indicating post-transcriptional and/or post-translational regulation of these cytokines. Due
to highly variable levels among individual patients, however, no significant differences were observed for
any cytokine mRNA between primary-culture and repeated-passage RA-SFB (ninth passage). Likewise,
no significant differences were detectable between RA-SFB and normal-skin fibroblasts (primary-culture
and repeated-passage). By producing high amounts of IL-6 and limited amounts of TNF-α, RA-SFB may
contribute to the (im)balance of proinflammatory and anti-inflammatory cytokines in the inflamed joint.
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immunodeficiency) [3–5], is associated with the produc-
tion of proinflammatory cytokines. Exuberant concentra-
tions of various cytokines have been detected within the
arthritic joint, such as tumor necrosis factor (TNF)-α [6]),
interleukin (IL)-1β [7], IL-6 [8], and IL-8 [9]. Other
cytokines have also been detected, including IL-10 [10],
IL-13 [11], IL-15 [12], and IL-18 [1,13], although these
have appeared to be less prominent. The production of
some of those cytokines in RA joints, in particular IL-6
[14], IL-15 [15], and IL-18 [13], has been at least partially
attributed to SFB. This cytokine production may drive or
control many of the characteristic features of rheumatoid
inflammation and may also contribute to the arthritogenic
potential of RA-SFB in SCID transfer models [4,5].
However, conflicting data exist about the inherent activa-
tion pattern of RA-SFB in culture, which may be in part
related to differing isolation methods [16–18]. In contrast
to conventional procedures (collagenase digest or tissue
outgrowth), which require repeated passages in order to
isolate sufficient numbers of pure SFB [17,18], we have
recently published a protocol for obtaining pure fibroblasts
from primary culture using anti-CD14 Dynabeads® to
deplete contaminating macrophages [16]. In these
studies, primary-culture RA-SFB clearly differed from
fourth-passage SFB in phenotypic and functional features,
indicating considerable alteration in culture. To investigate
whether similar problems apply to their expression of
cytokines, this functional feature was comparatively ana-
lyzed in RA-SFB isolated by different methods. Normal-
skin fibroblasts were used as noninflammatory controls.
Materials and methods
Synovial tissue was obtained after joint surgery from
patients with RA (n=18) who had given their informed
consent. The patients met the American College of
Rheumatology 1987 revised criteria for the classification
of RA [19]. Foreskin samples were obtained from six
healthy individuals. The study was approved by the Institu-
tional Review Board of the University of Leipzig. RA-SFB
were isolated either by trypsin/collagenase (Roche,
Mannheim, Germany) digestion, short-term in vitro adher-
ence (7 days) to remove nonadherent cells, and negative
isolation using magnetobead-coupled anti-CD14 mono-
clonal antibodies (primary-culture RA-SFB) [16] or by out-
growth from tissue pieces (repeated-passage RA-SFB;
Table 1), a conventional isolation procedure previously
used in a number of studies.
Skin fibroblasts (FB) were obtained either by Dispase
II/collagenase (Roche) digestion of normal skin samples
(primary-culture normal-skin FB) or by tissue outgrowth
from normal skin (repeated-passage normal-skin FB) (see
Table 1). The phenotype and composition of isolated/pas-
saged FB were characterized by flow cytometry in a fluo-
rescence-activated cell sorter (FACS), using saturating
amounts of the monoclonal antibodies listed in Table 2
and a FACS Calibur flow cytometer (Becton Dickinson,
San Jose, CA) for analysis.
Cytokine concentrations in supernatants of primary-culture
and repeated-passage RA-SFB (n=3 each) were assessed
using commercial ELISA kits for IL-1β, IL-6, TNF-α (DPC,
Bad Nauheim, Germany), IL-10, IL-13, IL-15 (R&D, Wies-
baden, Germany), and IL-18 (Diaclone, Besançon,
France), following the manufacturer’s protocols. Cytokine
mRNA was quantified by isolating the total RNA [20], con-
verting it to cDNA by standard procedures [21], and
amplifying the DNA by PCR using specific primers for the
cytokines TNF-α, IL-1β, IL-6, IL-10, IL-13, IL-15, and IL-18.
Quantification of relative units of cDNA was performed
using  32P-end-labeled oligonucleotides as probes [22],
normalizing the relative concentrations of cytokine cDNA
to those of cyclophilin. Lipopolysaccharide-stimulated
peripheral blood mononuclear cells (PBMC) were used as
positive controls for cDNA quantification of IL-1β, IL-10,
TNF-α, and IL-13; TNF-α- and IL-1β-stimulated primary-
culture normal-skin FB were used as controls for IL-6, IL-
15, and IL-18. Controls were designed to yield maximum
expression of the relevant cytokine mRNA.
For statistical analysis, only PCR experiments with a coef-
ficient of determination r2 > 0.9 in linear regression were
used. The mRNA levels of different FB were compared
using the Kruskal–Wallis test followed by the Mann–
Whitney rank sum test. Correlations between clinical
Table 1
Source and characteristics of fibroblasts used for mRNA quantification
Source of isolated cells Number of patients Method of cell isolation Median no. of passages (range)
Rheumatoid arthritis (synovial membrane)
Primary culture 5 Collagenase digest 0
Passage ≥5 7 Tissue outgrowth 9 (5–14)
Foreskin (normal skin)
Primary culture 6 Collagenase digest 0
Passage ≥5 6 Tissue outgrowth 5.5 (5–13)parameters of each patient (age, rheumatoid factor,
disease duration) and cytokine mRNA levels were calcu-
lated using the Spearman rank correlation. In all cases,
differences were considered statistically significant at the
level P ≤ 0.05.
Results
Composition of isolated/passaged fibroblasts
All cell preparations were highly enriched for FB, as deter-
mined by positivity for prolyl-4-hydroxylase  and for CD90
(mAb [monoclonal antibody] AS02 [23]; Fig. 1 and
Tables 2 and 3). Contamination with CD3+ T cells, CD19+
B cells, CD14+ and/or CD68+ macrophages, and vWF+
and CD31+ endothelial cells was routinely below 2% with
the exception of primary-culture normal-skin FB, which con-
tained approximately 6% vWF+ (von Willebrand’s factor-
positive) and CD31+ cells (see Fig. 1 and Tables 2 and 3).
Quantification of cytokine protein
First-passage RA-SFB secreted large amounts of IL-6 but
only small amounts of TNF-α or IL-10 (one of three
samples positive) (Table 4). IL-1β, IL-15, and IL-18 protein
was not detectable (see Table 4). In repeated-passage
RA-SFB (tenth-passage), cytokine secretion was signifi-
cantly lower for IL-6 and TNF-α and was markedly lower
for IL-10 (one of three samples positive) (see Table 4).
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Table 2
Monoclonal antibodies used in the present study
Cellular target Antigen Clone Labeling Source
All human cells HLA-ABC W6/32 None DAKO, Hamburg, Germany
Fibroblasts CD90 (Thy-1) FibAS02 None Dianova, Hamburg, Germany
Collagen-producing cells Prolyl-4-hydroxylase 3-2B12 None Calbiochem, Bad Soden, Germany
Antigen-presenting cells (MHC class II) HLA-DP, DQ, DR CR3/43 None DAKO
Monocytes, macrophages CD68 KP1 FITC DAKO
Monocytes CD14 MφP9 FITC Becton Dickinson, Heidelberg, Germany
B cells CD19 HD37 None DAKO
T cells CD3 UCHT1 None DAKO
Endothelial cells, some leukocytes CD31 (glycoprotein IIa) JC/70A None DAKO
Endothelial cells von Willebrand’s factor 4F9 None Immunotech, Marseilles, France
Table 3
Characterization of synovial and skin fibroblasts by flow cytometry
Rheumatoid arthritis synovial fibroblasts
Antigen Primary-culture (n = 4) Repeated-passage (n = 4) Primary-culture normal-skin FB (n = 4)
MHC class I (HLA-ABC) 98.3 ± 0.8 97.6 ± 1.1 98.5 ± 0.5
Prolyl-4-hydroxylase (intracellular) 96.5 ± 2.0 98.5 ± 0.5 98.1 ± 0.3
CD90 (Thy-1) 92.7 ± 4.4 98.9 ± 0.3 88.8 ± 3.8
MHC class II (HLA-DP, DQ, DR) 3.8 ± 3.1 0.3 ± 0.4 3.1 ± 2.3
CD14 0.1 ± 0.1 0.2 ± 0.2 0.1 ± 0.1
CD68 0.6 ± 0.7 0.2 ± 0.1 0.3 ± 0.2
CD3 1.5 ± 1.0 0.3 ± 0.1 0.2 ± 0.4
CD19 0.5 ± 0.9 0.1 ± 0.1 0.3 ± 0.4
von Willebrand’s factor (intracellular) 1.6 ± 1.6 0.1 ± 0.1 6.0 ± 3.1
CD31 0.1 ± 0.1 0.2 ± 0.1 6.1 ± 3.2
Values are means ± SD of positive cells. Intracellular, antigens detected following permeabilization of the cells; the remaining antigens were
detected by surface staining. FB = fibroblasts.Arthritis Research    Vol 4 No 2 Hirth et al.
Figure 1
Expression of surface and intracellular molecules in primary-culture or repeated-passage rheumatoid arthritis synovial fibroblasts (RA-SFB) and in
primary-culture normal-skin fibroblasts (FB). All preparations were highly enriched for FB, as demonstrated by expression of prolyl-4-hydroxylase
and CD90 (Thy-1). Contamination with endothelial cells (indicated by von Willebrand’s factor), T cells (indicated by CD3), B cells (indicated by
CD19), and macrophages (indicated by CD14) was below 2%, with the exception of contaminating endothelial cells in primary-culture normal-skin
FB, which averaged approximately 6% (see Table 3). , controls; , cell markers; M1, gate set in order to exclude 99% of the cells stained with
the respective isotype control; percentages indicate the percentage of cells positive for each marker, numbers on the x axis indicate fluorescence
channels.Quantification of cytokine mRNA
The lack of IL-1β, IL-15, and IL-18 protein secretion by
first-passage RA-SFB was reflected by very low levels of
mRNA in primary-culture cells (Fig. 2). Whereas the
decrease of IL-10 protein secretion in RA-SFB from the
first to the tenth passage was paralleled by a correspond-
ing decrease in mRNA levels (only one positive sample in
the ninth passage), the levels of mRNA for IL-6 and TNF-α
increased with time (20-fold and 300-fold increase of the
median, respectively), suggesting post-transcriptional or
post-translational regulation (see Fig. 2). There were large
variations of the cytokine mRNA levels between individual
patients, conceivably preventing significant differences
among groups (see Fig. 2).
Interestingly, mRNA for IL-10 was detected only in three of
five primary-culture RA-SFB samples and two of six
primary-culture normal-skin FB samples. Limited IL-10
expression would be compatible with a minimal contami-
nation of macrophages (approximately 0.7%) demon-
strated by FACS. Passaged SFB or skin FB contained
only individual positive samples (see Fig. 2).
IL-18 mRNA was present in three of six primary-culture
normal-skin FB samples and in two of six repeated-
passage normal-skin FB but was not detectable in
primary-culture and repeated-passage RA-SFB (see
Fig. 2).
IL-13 mRNA was not detectable in any of the FB samples;
in contrast, IL-13 mRNA was readily detectable in
lipopolysaccharide-stimulated PBMC used as positive
control (data not shown).
No significant correlations (Spearman rank correlation)
were observed between the age, rheumatoid factor status,
or disease duration of individual RA patients and the
cytokine mRNA levels in SFB.
Discussion
The present study demonstrates considerable alterations
in the cytokine expression of repeated-passage RA-SFB
upon extended in vitro culture, as shown by significantly
lower protein concentrations for IL-6 and TNF-α and non-
significant changes in the mRNA levels for almost all
cytokines. These findings are important because most
studies have been performed with fibroblasts at higher
passage (3–10), which are prone to similar alteration in
vitro. They also point to the suitability/usefulness of iso-
lated early-passage cells for studies on the features/func-
tional characteristics of SFB in RA.
Composition of isolated and passaged fibroblasts
A high percentage of RA-SFB positive for FB markers
(≥97%) and a contamination of <2% leukocytes and
endothelial cells indicated a limited contribution of conta-
minating cells to the cytokine expression. Primary-culture
normal-skin FB, however, showed a contamination of
approximately 6% endothelial cells, possibly accounting
for the detection of IL-18 mRNA.
Cytokine expression in RA-SFB
IL-6, a pleiotropic cytokine produced predominantly by
synovial macrophages and fibroblasts, plays a major role
in cellular activation. The detection of high levels of IL-6
mRNA/protein (see Fig. 2 and Table 4) agrees with previ-
ous observations in passaged SFB/synoviocytes [24–28].
In those studies, however, stimulation of cells with IL-1β or
TNF-α was necessary to induce the production of 80–90
ng/ml of IL-6 [25]. In the present study, in contrast, first-
passage RA-SFB constitutively secreted IL-6. This indi-
cates a high intrinsic activation status of the cells, i.e.
retention of in vivo features present before removal from
the synovial membrane [29]. A clearly decreased IL-6 pro-
duction in repeated-passage RA-SFB (see Table 4) may
represent culture alterations due to the lack of cytokine
stimulation.
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Table 4
Cytokine concentrations in supernatants of rheumatoid arthritis synovial fibroblast (RA-SFB) cultures (pg/ml)
RA-SFB
Cytokine Detection limit of the ELISA (pg/ml) First passage (n = 3) Tenth passage (n = 3)
IL-1β 5 Not detectable Not detectable
IL-6 5 15,800 ± 2110 790.0 ± 35.6*
IL-10 1.5 35.7 ± 34.2b 9.0 ± 7.5b
IL-15 1 Not detectable Not detectable
IL-18 94 Not detectable Not detectable
TNF-α 1.7 22.1 ± 1.1 15.1 ± 0.7*
bCytokine detected in only one of three samples. *P ≤ 0.05 in comparison with first-passage RA-SFB.IL-10 is produced by T cells, B cells, mast cells, and acti-
vated monocytes or macrophages. Its primary function
appears to limit and terminate inflammatory responses
(including those in experimental arthritis). In contrast to
recent suggestions [30], the capability of RA-SFB to
produce IL-10 remains uncertain. First, synovial
macrophages, rather than SFB, are known to produce con-
siderable amounts of IL-10 [31, reviewed in 32]. Second,
the low amounts of IL-10 detected in primary-culture RA-
SFB in the present study are probably the product of the
few remaining macrophages (see Table 3). This hypothesis
is supported by the lack of IL-10 protein/mRNA detected in
most repeated-passage RA-SFB (only one positive sample
each), which lack contaminating macrophages.
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Figure 2
Quantification of cytokine mRNA in primary-culture (n=   5) or repeated-passage RA-SFB (n=   7) and primary-culture or repeated-passage normal-
skin FB (n=   6 each). Levels of mRNA (relative units) for the various cytokines were determined by semiquantitative RT-PCR and normalized to
those of the housekeeping gene cyclophilin. Data are expressed as box plots showing the median and percentiles 25 and 75. The dotted line in
each graph depicts the cytokine mRNA level in stimulated control cells (i.e. lipopolysaccharide-stimulated peripheral blood mononuclear cells for IL-
1β, IL-10, and TNF-α; and TNF-α and IL-1β-stimulated primary-culture normal-skin FB for IL-6, IL-15, and IL-18). Large, filled dots represent mRNA
levels in individual patients outside the 25th and 75th percentiles. FB = fibroblasts; RA-SFB = rheumatoid arthritis synovial fibroblasts.Similarly, the proinflammatory cytokine TNF-α is predomi-
nantly produced by synovial macrophages [25,33,34], and
not by SFB [35–37]. In contrast to IL-10, however, TNF-α
protein or mRNA were also detected in repeated-passage
RA-SFB (lacking contaminating macrophages). TNF-α
may therefore be a genuine product of RA-SFB, allowing
these cells to contribute to synovial inflammation. Its signif-
icantly decreased production in repeated-passage RA-
SFB may reflect either loss of macrophages and/or in vitro
alterations of SFB due to withdrawal of cytokine stimula-
tion.
In this study, no IL-1β protein (and only minimal amounts
of IL-1β mRNA) was detected in primary-culture and
repeated-passage RA-SFB. This result is in contrast to
reports showing IL-1β mRNA or protein in nonstimulated
RA-SFB [24,38]; however, it confirms findings that
showed expression of IL-1β mRNA but lack of secretion of
IL-1β protein by RA-SFB [39]. As for TNF-α, the detection
of IL-1β mRNA in repeated-passage RA-SFB suggests
some IL-1β transcription.
IL-13 is an anti-inflammatory cytokine expressed in a
subset of activated T cells. It downregulates macrophage
activity and thereby reduces the production of proinflam-
matory cytokines. IL-13 mRNA was not detectable in any
of the FB preparations assayed, in good agreement with
the lack of IL-13 protein production by passaged RA-SFB,
whether nonstimulated or after stimulation with IL-1β,
TNF-α, or lipopolysaccharide [40]. Therefore, it appears
that RA-SFB do not contribute to the local production of
this potent anti-inflammatory cytokine [11,40].
IL-15, an IL-2-like cytokine produced by monocytes/
macrophages, dendritic cells, fibroblasts, and bone-
marrow stroma cells, activates cell proliferation, cytotoxity,
and cytokine production in natural killer cells and is a
potent chemoattractant for T cells. Low levels of IL-15
mRNA were detected in all FB preparations; however, IL-
15 protein was absent in the supernatants of first-passage
or repeated-passage RA-SFB (see Fig. 2, Table 4). This
finding is in contrast to reports showing IL-15 mRNA and
protein in repeated-passage SFB cell lines (approximately
50 pg/ml; [15]). However, a lower expression of IL-15
mRNA in SFB cell lines in comparison with freshly isolated
synovial tissue cells (containing synovial macrophages, the
predominant producers of IL-15 [12,15]) strongly indi-
cates that RA-SFB produce very little, if any, IL-15 [12].
IL-18 is produced by PBMC, dendritic cells, and activated
endothelial cells and has pleiotropic effects on T cell func-
tions. The failure to detect IL-18 mRNA or protein in non-
stimulated, primary-culture, or repeated-passage RA-SFB
confirms previous reports in nonstimulated, passaged RA-
SFB lines [13]. The capability of FB to express IL-18
mRNA [13] was confirmed by its detection in nonstimu-
lated (see Fig. 2) and TNF-α/IL-1β-stimulated primary-
culture normal-skin FB (dotted line in Fig. 2). However, we
cannot exclude the possibility that contaminating endothe-
lial cells were a source of IL-18 mRNA in these cultures
[13].
Interestingly, the cytokines IL-1β, IL-6, IL-15, and TNF-α in
RA-SFB showed a dissociated pattern of mRNA and
protein expression, suggesting post-transcriptional or
post-translational regulation. Such regulation (at the level
of mRNA stability, translational efficacy, stability of the
protein product or other post-translational modifications)
has been demonstrated for IL-1β [41–43], IL-6 [44,45],
IL-15 [46], and TNF-α [47]. Its importance for RA-SFB
functions remains to be analyzed.
Phenotype of RA-SFB
In contrast to our earlier findings [16], which confirmed
reports on the expression of MHC-II in the RA/OA synovial
membrane [48-51], in the present study only 4% of RA-
SFB expressed MHC-II molecules (see Table 3). Possible
explanations include differences in isolation procedures, in
the patient populations analyzed, and in the epitopes of
the MHC molecules recognized by the respective mono-
clonal antibodies [37,52].
Conclusion
On the basis of the present results, the arthritogenic and
tissue-destructive properties of RA-SFB in the inflamed
rheumatoid joint may be supported by production of high
amounts of IL-6 and limited amounts of TNF-α. Early-
passage RA-SFB provide a source of cells with limited
alteration from the in vivo phenotype/functional features
and allow future studies comparing early- with late-stage
RA; RA with normal and inflammatory controls; and in vivo
with  in vitro cytokine production by RA-SFB. Post-tran-
scriptional and post-translational regulation of cytokine
production and large variability among samples must be
taken into consideration.
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Supplementary material
Supplementary materials and methods
Patients and controls
Synovial tissue was obtained by joint surgery from patients
with RA (n=18) who met the American College of
Rheumatology 1987 revised criteria for the classification
of the disease [19]. As controls, FB were isolated from six
foreskin samples from healthy individuals. The source and
characteristics of the specimens used in the study are
shown in Table 1. Written, informed consent was obtained
from all patients before specimens were collected. The
study was approved by the Institutional Review Board of
the University of Leipzig.
Tissue samples
Tissue samples were placed in cell-culture medium containing
DMEM and RPMI 1640 (1:2), 10% FCS, 25mM HEPES,
penicillin (100U/ml), and streptomycin (100 µg/ml; all Gibco,
Eggenstein, Germany; hereafter called culture medium) at
ambient temperature and processed within 2 hours. RA syn-
ovial membrane specimens were washed in culture
medium, fat and fibrous tissue were removed, and the
remaining synovial tissue was used for further preparation.
Isolation of synovial fibroblasts and skin fibroblasts
Isolation of SFB from the RA synovial membrane and of
skin FB was performed by two different protocols. For the
preparation of primary-culture RA-SFB, synovectomy
samples were minced and digested for 30 min at 37°C in
phosphate buffered saline (PBS; Gibco) containing 0.1%
trypsin followed by a digestion step with 0.1% collage-
nase P (Boehringer Mannheim, Germany) in culture
medium at 37°C. To resolve cell aggregates, the suspen-
sion was filtered through a sterile sieve (80 mesh, Sigma,
Deisenhofen, Germany). The cells were collected by cen-
trifugation after two washing steps with medium and cul-
tured for 7 days in culture medium at 37°C in a humidified
atmosphere containing 5% CO2. The nonadherent cells
were depleted by medium exchange every 2–3 days.
Macrophages were then depleted by incubation with
CD14-coated Dynabeads® (Dynal, Oslo, Norway) as
follows: Trypsinized and washed synovial cells from
primary culture (107/ml) were incubated with 4 × 107/ml
Dynabeads® M-450 CD14 (clone RMO52; Dynal) in
PBS/2% FCS for 1 hour at 4°C with bidirectional rotation.
Nine ml of PBS/2% FCS was added and the conjugated
cells were collected by using the Dynal Magnetic Particle
Concentrator®. Unconjugated SFB were collected,
washed twice in PBS/2 % FCS, and used for mRNA
preparation. Primary-culture normal-skin FB were prepared
by first incubating skin samples with Dispase II (0.5 U/ml;
Boehringer Mannheim) overnight at 4°C, removing the epi-
dermis, and digesting the rest with 0.25% collagenase P
(Boehringer Mannheim) in DMEM/1% FCS at 37°C and
5% CO2 for 4 hours. For the preparation of repeated-
passage RA-SFB and repeated-passage skin FB, cells
were obtained by outgrowth from tissue pieces. Small
samples of synovial membrane or skin (in the latter case,
after overnight incubation with 0.5 U/ml Dispase II
[Boehringer Mannheim] at 4°C and removal of the epider-
mis) with a volume of approximately 30 mm³ were cultured
in triplicate for 1–2 weeks using 75-cm² culture flasks
(Greiner, Solingen, Germany). At confluency, the cells
were trypsinized with trypsin–EDTA (0.25% trypsin/0.2%
EDTA; Gibco) for 5 min and passaged 1:2 in 150 cm²
culture flasks. SFB were used from passages 5 to 14, and
skin FB from passages 5 to 13. Passaged SFB and skin
FB were tested every 14 days for contamination with
Mycoplasma spp. by ELISA (Boehringer Mannheim).
Flow cytometry
The purity and phenotype of the isolated fibroblasts were
characterized by flow cytometry. Cultured cells were har-
vested with trypsin/EDTA (Gibco) and washed twice in
Available online http://arthritis-research.com/content/4/2/117PBS. The cells (2 × 105) were stained with saturating
amounts of one of the monoclonal antibodies listed in
Table 2 for 30 min at 4°C. In all cases, except for fluores-
cein isothiocyanate (FITC)-labeled primary monoclonal
antibodies, secondary labeling was performed for 30 min
at 4°C with an FITC-labeled goat-anti mouse immuno-
globulin (DAKO, Hamburg, Germany). For the detection
of intracellular antigens, permeabilzation of the cells was
performed using 0.5% saponine as previously described
[16]. Cells were analyzed with the FACS Calibur flow
cytometer (Becton Dickinson, San Jose, CA). A gate was
set to exclude 99% of the cells stained with control
immunoglobulin.
Preparation of mRNA and generation of complementary
DNA (cDNA)
Total RNA was isolated by a single step guanidinium thio-
cyanate-phenol-chloroform method [20] using Tri-Reagent
(Sigma, Deisenhofen, Germany) following the manufac-
turer´s protocol. The RNA-pellet was dissolved in
H2O/0.1% diethyl pyrocarbonate, and the OD260 was
determined in a UV spectrophotometer. Ten to sixty micro-
grams of RNA was obtained per sample. For first-strand
DNA synthesis, 2 µg of total RNA was converted to cDNA
by incubation with 5 U of avian myeloblastosis virus
reverse transcriptase (Promega, Mannheim, Germany),
20 µg/ml oligo(dT) primers (pd(T)12-18; Pharmacia LKB,
Uppsala, Sweden) and 1 mM dNTPs for 1 hour at 42°C in
a total volume of 20 µl. The cDNA was stored at –20°C
until analysis.
Amplification and quantification of target DNA
Before performing semiquantitative PCR experiments,
kinetic experiments were carried out to determine the
number of amplification cycles for exponential product
accumulation. For PCR, 2 µl of the cDNA preparations
were incubated with 0.5 U/ml Taq DNA polymerase
(Perkin Elmer, Weiterstadt, Germany) in the presence of
1.5 mM mgCl2, 0.4 µM oligonucleotide primers, and
0.2 mM dNTPs (Pharmacia). Amplification was performed
with a Gene Amp PCR-System 9700 (Applied Biosys-
tems, Weiterstadt, Germany) using the following condi-
tions: denaturation at 94°C for 5 min, followed by
repetitive cycles of denaturation at 94°C (45 s), annealing
at 60°C (45 s), and polymerization at 72°C (45 s). The
primers and the hybridization probes specific for IL-1β,
IL-6, and TNF-α were purchased from Clontech Laborato-
ries (Palo Alto, CA). The primers and the probes specific
for IL-13 [11], IL-10 [10], IL-15 [46], IL-18 [13], and the
constitutively expressed cyclophilin mRNA [S1] were
deduced from the published sequences and controlled for
cross-reactivity by gene-bank search (IL-13: sense 5′-ACA
GCT GGC ATG TAC TGT GC-3′, antisense 5′-GTT GCC
TGT GTG TGA AGT GG-3′, hybridization probe 5′-TAG
CTT AGA CTT CAG CCT GTG C-3′; IL-10: sense 5′-
ATG CCC CAA GCT GAG AAC CAA GAC CCA-3′, anti-
sense 5′-TCT CAA GGG GCT GGG TCA GCT ATC
CCA-3′, hybridization probe 5′-CAT TCT TCA CCT GCT
CCA CG-3′; IL-15: sense 5′-CAG GAC TCG ATG GAG
AAT CC-3′, antisense 5′-CAT GAA TAC TTG CAT CTC
CGG-3′, hybridization probe 5′-CCA TCA TGT TCC ATG
CTG C-3′; and IL-18: sense 5′-ACC TCA GAC CTT CCA
GAT CG-3′, antisense 5′-TCA GGC TGG TCT TGA ACA
CC-3′, hybridization probe 5′-TTG TCG CAG GAA TAA
AGA TGG-3′).
Quantification of relative amounts of cytokine cDNA
Quantification of cDNA was performed using a radioactive
protocol that has previously been shown to be highly sensi-
tive and reproducible for similar types of experiments
[21,22]. In brief, cDNA containing the gene of interest
(positive control) was diluted over a five-log scale and
samples of each dilution were simultaneously amplified by
PCR. For each cytokine, samples from all fibroblasts were
simultaneously amplified in duplicates to minimize inter-
assay variations. After the amplification, a sample of each
PCR product was transferred onto a nylon membrane
(Zeta-Probe Blotting membrane, Bio-Rad Laboratories,
Richmond, CA, USA) by alkaline transfer using a slot blot
apparatus. Blots were incubated for at least 1 hour at
52.5°C in hybridization fluid containing 6 × sodium chlo-
ride, sodium citrate (SSC), 4% Denhardt’s solution, 10 mM
EDTA, 100 µg/ml denatured, fragmented salmon-sperm
DNA, and 1% SDS. Amplified target DNA was detected by
incubation of the blots in hybridization buffer containing
target-DNA-specific  γ-32P-labeled probes for at least
8 hours at 52.5°C. Probes were end-labeled with γ-32P
using T4 polynucleotide kinase (Promega) as described
elsewhere [21,22]. The blots were washed, and hybridized
probes were quantified with a radioanalytic imaging system
(Bio-Rad). Background counts from areas of the blot con-
taining no amplified sequence (water controls) were sub-
tracted. The amount of hybridized probe was found to be
linearly related to the amount of the PCR products in the
samples. Using the standard curve obtained by amplifica-
tion of dilutions of the positive controls (lipopolysaccharide-
stimulated PBMC or TNF-α- and IL-1β-stimulated
primary-culture normal-skin FB), the relative concentration
of initial target DNA in each individual sample could be cal-
culated. The ubiquitously expressed housekeeping gene
cyclophilin was used to normalize the amount of cDNA
employed in each RT-PCR reaction. The results were
expressed as relative units. The sizes of the amplification
products were controlled by agarose-gel electrophoresis.
Cytokine ELISA
To assess the concentration of secreted cytokines, super-
natants of primary-culture RA-SFB and repeated-passage
RA-SFB were analyzed using commercially available
ELISA kits for IL-1β, IL-6, TNF-α (DPC), IL-10, IL-13, IL-15
(R&D), and IL-18 (Diaclone), in accordance with the manu-
facturers’ protocols.
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The standard curve for each PCR experiment was deter-
mined by linear regression analysis. Only experiments with
a coefficient of determination r2 > 0.9 were used for this
study. Protein/mRNA levels of RA-SFB and of normal-skin
FB were compared using the Kruskal–Wallis test followed
by the Mann–Whitney rank sum test. Correlations
between clinical parameters from each patient (age,
rheumatoid factor, disease duration) and cytokine mRNA
levels were assessed using the Spearman rank correlation
test. In all cases, differences were considered statistically
significant if P ≤ 0.05.
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